CLINICAL_TRIALS
trial_result
· 2026-03-12
Clinical Trial Update: 2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML [Phase 1]
Summary
A Phase 1 trial of CRD3874-SI for relapsed or refractory acute myeloid leukemia has been suspended.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Maryland, Baltimore | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: SUSPENDED